Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Temperature and Salting out Effects on Nicotine Dissolution Kinetics in Saline Solutions.

ACS omega·2020

Same author

Filamentous Escherichia coli cells swimming in tapered microcapillaries.

Research in microbiology·2014

Same author

Video microscopic high-temperature measurement of surface tension.

Journal of colloid and interface science·2013

Same author

Visualization and quantification of two-phase flow in transparent miniature packed beds.

Physical review. E, Statistical, nonlinear, and soft matter physics·2012

Same author

{N-[1-(1H-Benzimidazol-2-yl)ethyl-idene-κN]-3-(1H-imidazol-1-yl)propan-1-amine-κN}dibromidomercury(II).

Acta crystallographica. Section E, Structure reports online·2012

Same author

The validation of complete Fourier direct MR method for diffusion MRI via biological and numerical phantoms.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2012

Search research articles

Related Experiment Video

Updated: May 20, 2026

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

Published on: March 17, 2023

Cationic liposomes in double emulsions for controlled release.

Qing Wang¹, Edith C Rojas, Kyriakos D Papadopoulos

¹Department of Chemical & Biomolecular Engineering, Tulane University, New Orleans, LA 70118, USA.

Journal of Colloid and Interface Science

|July 17, 2012

Summary

This study developed a double-encapsulation system using liposomes in W(1)/O/W(2) emulsions for optimized dermal vaccine delivery. Freeze-thaw cycles control liposome release, with L-α-phosphatidylcholine concentration tuning the release rate.

More Related Videos

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

Related Experiment Videos

Last Updated: May 20, 2026

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

On-Chip Octanol-Assisted Liposome Assembly for Bioengineering

Published on: March 17, 2023

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

Area of Science:

Pharmaceutical Sciences
Materials Science
Biotechnology

Background:

Liposomes are effective drug delivery vehicles, but their stability can be compromised by external conditions.
Dermal vaccine delivery requires systems that protect active components and enhance skin penetration.
Cationic liposomes offer improved skin penetration and adjuvant properties for vaccines.

Purpose of the Study:

To develop a novel double-encapsulation system for protecting liposomes within W(1)/O/W(2) emulsions.
To optimize this system for effective dermal vaccine delivery.
To investigate the release mechanism and control factors for liposomes from the emulsion.

Main Methods:

Formulation of W(1)/O/W(2) double emulsions encapsulating liposomes in the W(1) phase.
Cryo-Scanning Electron Microscopy (Cryo-SEM) to visualize liposome integrity.
Controlled freeze-thaw cycles to induce liposome release.
Varied L-α-phosphatidylcholine (PC) concentration in liposomes to study release kinetics.

Main Results:

Liposomes were successfully encapsulated within the W(1) phase, remaining intact during formulation.
Freeze-thaw treatment of the oil phase induced progressive liposome release via internal and external coalescence.
The release rate of liposomes was effectively controlled by adjusting the L-α-phosphatidylcholine (PC) concentration.

Conclusions:

The developed W(1)/O/W(2) double emulsion system provides robust protection for encapsulated liposomes.
Freeze-thaw-induced release offers a tunable mechanism for delivering liposomes and their contents.
This system holds promise for advanced dermal vaccine delivery applications, leveraging cationic liposomes' properties.